Association between the overexpression of PBOV1 and the prognosis of patients with hepatocellular carcinoma

Xue,Chengbiao; Zhong,Zibiao; Ye,Shaojun; Wang,Yanfeng; Ye,Qifa

doi:10.3892/ol.2018.9013

Association between the overexpression of PBOV1 and the prognosis of patients with hepatocellular carcinoma

Authors:
- Chengbiao Xue
- Zibiao Zhong
- Shaojun Ye
- Yanfeng Wang
- Qifa Ye
View Affiliations

Affiliations: Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, Hubei 430071, P.R. China
Published online on: June 25, 2018 https://doi.org/10.3892/ol.2018.9013
Pages: 3401-3407

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate and breast cancer overexpressed 1 (PBOV1) is a known human protein‑coding gene with an uncharacterized function; it has been demonstrated to be overexpressed in a variety of human cancer types. The overexpression of PBOV1 has been indicated as significantly associated with the poor prognosis of these types of cancer. However, the function of PBOV1 in hepatocellular carcinoma (HCC) has not yet been elucidated. The present study was designed to evaluate the expression and prognostic significance of PBOV1 in HCC. Reverse transcription‑quantitative polymerase chain reaction and western blot analyses were conducted to measure the expression of PBOV1 in HCC cell lines and tissues. The associations between PBOV1 expression and clinicopathological features were statistically analyzed. The association between PBOV1 expression and the prognosis of HCC patients was analyzed by the Kaplan‑Meier method. The mRNA and protein expression levels of PBOV1 were significantly increased in the HCC cell lines and HCC tissues (all P<0.05) compared with normal cell lines and tissues. In addition, PBOV1 expression was significantly associated with maximal tumor size (P=0.032), tumor metastasis (P=0.035) and tumor stage (P=0.017). The Kaplan‑Meier survival curves indicated that overall survival was significantly poorer in patients with HCC with PBOV1 overexpression (P<0.05) compared with patients with low expression levels. The multivariate analysis indicated that high PBOV1 expression was an independent predictor of poor overall survival. To the best of our knowledge, the data of the present study describes the expression pattern of PBOV1 in HCC for the first time, and also suggests that PBOV1 may serve as a valuable prognostic biomarker for HCC.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Cui Y and Jia J: Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 28 Suppl 1:S7–S10. 2013. View Article : Google Scholar
3	Fattovich G, Stroffolini T, Zagni I and Donato F: Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology. 127 5 Suppl 1:S35–S50. 2004. View Article : Google Scholar : PubMed/NCBI
4	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
5	Block TM, Mehta AS, Fimmel CJ and Jordan R: Molecular viral oncology of hepatocellular carcinoma. Oncogene. 22:5093–5107. 2003. View Article : Google Scholar : PubMed/NCBI
6	Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
7	An G, Ng AY, Meka CS, Luo G, Bright SP, Cazares L, Wright GL Jr and Veltri RW: Cloning and characterization of UROC28, a novel gene overexpressed in prostate, breast, and bladder cancers. Cancer Res. 60:7014–7020. 2000.PubMed/NCBI
8	Loizidou MA, Cariolou MA, Neuhausen SL, Newbold RF, Bashiardes E, Marcou Y, Michael T, Daniel M, Kakouri E, Papadopoulos P, et al: Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population. Breast Cancer Res Treat. 121:147–156. 2010. View Article : Google Scholar : PubMed/NCBI
9	Samusik N, Krukovskaya L, Meln I, Shilov E and Kozlov AP: PBOV1 is a human de novo gene with tumor-specific expression that is associated with a positive clinical outcome of cancer. PLoS One. 8:e561622013. View Article : Google Scholar : PubMed/NCBI
10	Doak SH, Jenkins SA, Hurle RA, Varma M, Hawizy A, Kynaston HG and Parry JM: Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Cancer Genet Cytogenet. 176:161–165. 2007. View Article : Google Scholar : PubMed/NCBI
11	Pan T, Wu R, Liu B, Wen H, Tu Z, Guo J, Yang J and Shen G: PBOV1 promotes prostate cancer proliferation by promoting G1/S transition. Onco Targets Ther. 9:787–795. 2016. View Article : Google Scholar : PubMed/NCBI
12	Krukovskaia LL, Samusik ND, Shilov ES, Polev DE and Kozlov AP: Tumor-specific expression of PBOV1, a new gene in evolution. Vopr Onkol. 56:327–332. 2010.(In Russian). PubMed/NCBI
13	Kamagata C, Tsuji N, Kondoh K, Sasaki M, Kobayashi D, Yagihashi A and Watanabe N: Enhanced expression of the UROC28 gene in human breast cancer: Relationship to ERBB2 gene expression. Anticancer Res. 22:4087–4091. 2002.PubMed/NCBI
14	Wang L, Niu CH, Wu S, Wu HM, Ouyang F, He M and He SY: PBOV1 correlates with progression of ovarian cancer and inhibits proliferation of ovarian cancer cells. Oncol Rep. 35:488–496. 2016. View Article : Google Scholar : PubMed/NCBI
15	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC cancer staging manual. 7th ed. Springer; New York: pp. 191–200. 2010
16	Yamashita Y, Taketomi A, Shirabe K, Aishima S, Tsuijita E, Morita K, Kayashima H and Maehara Y: Outcomes of hepatic resection for huge hepatocellular carcinoma (≥10 cm in diameter). J Surg Oncol. 104:292–298. 2011. View Article : Google Scholar : PubMed/NCBI
17	Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, DeCaprio JA and Weinberg RA: Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 22:2111–2123. 2002. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Li J, Zhang N, Song LB, Liao WT, Jiang LL, Gong LY, Wu J, Yuan J, Zhang HZ, Zeng MS and Li M: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res. 14:3319–3326. 2008. View Article : Google Scholar : PubMed/NCBI
20	Song L, Wang L, Li Y, Xiong H, Wu J, Li J and Li M: Sam68 up-regulation correlates with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells. J Pathol. 222:227–237. 2010. View Article : Google Scholar : PubMed/NCBI
21	Ma W, Yu Q, Jiang J, Du X, Huang L, Zhao L and Zhou QI: miR-517a is an independent prognostic marker and contributes to cell migration and invasion in human colorectal cancer. Oncol Lett. 11:2583–2589. 2016. View Article : Google Scholar : PubMed/NCBI
22	Wang G, Huang J, Zhu H, Ju S, Wang H and Wang X: Overexpression of GRO-β is associated with an unfavorable outcome in colorectal cancer. Oncol Lett. 11:2391–2397. 2016. View Article : Google Scholar : PubMed/NCBI
23	Tang B, Tang F, Wang Z, Qi G, Liang X, Li B, Yuan S, Liu J, Yu S and He S: Overexpression of CTNND1 in hepatocellular carcinoma promotes carcinous characters through activation of Wnt/β-catenin signaling. J Exp Clin Cancer Res. 35:822016. View Article : Google Scholar : PubMed/NCBI